BALTIMORE, July 20, 2017/PRNewswire/–Paragon Bioservices, a global leader in the manufacturing of biopharmaceuticals and vaccines, announced today the appointment of Deborah Wild to the position of Vice President, Quality, and Regulatory Affairs, where she will focus on accelerating our quality agenda.
“We are building a world class team and Ms. Wild’s experience and leadership is spot on to support Paragon’s growth initiatives in GMP vaccine and viral vector manufacturing,” stated Peter Buzy, President, and CEO of Paragon. “Having both quality and manufacturing experience, Deb has a strong track record of executing plans that have added the profitability for the companies she has been employed by, both as an employee and as a consultant. We are excited to have Deborah join our senior team and to be a critical part of the Company’s future growth. We look forward to her contributions as we continue to grow the company.”
Ms. Wild is an accomplished Quality Executive/Leader with 30 years’ experience. Most recently she ran a thriving consulting practice, for over 14 years, leading Quality Assurance focused initiatives for high profile clients such as Genentech, TEVA, Polynoma, Cytovance, CMC Biologics, etc. Managing her consulting on the side, Ms. Wild occupied full-time roles at Polynoma as VP of Quality Systems and VP of Manufacturing and Supply Chain at Victory Pharma. Prior to launching her practice, she spent over 17 years at Genentech ending there as Director of Contract Manufacturing. Through her experience, Ms. Wild has earned a strong reputation for adding to company growth strategies by effectively transforming Quality organizations into strong business partners.
Additionally, Ms. Wild was a member of our armed forces serving in the Army having been deployed to Desert Storm towards the end of her enlistment. She began as a Private First Class and left having achieved the rank of Staff Sergeant.
About Paragon Bioservices, Inc.
Paragon Bioservices is a private-equity backed contract development and manufacturing organization (CDMO) whose focus is the development and manufacturing of biopharmaceuticals including the production and purification of monoclonal antibodies, recombinant proteins, viral vectors, and vaccines. The company provides research services, process development, and cGMP manufacturing. Paragon’s cGMP facilities include microbial and mammalian suites, fill-finish and fully-segregated virus facilities.